Liquidia, An IBD 50 Stock, Tops Sales Views Amid United Therapeutics Rivalry

Liquidia (LQDA) topped Wall Street's second-quarter expectations Wednesday arsenic income of its lung illness treatment, Yutrepia, grew by treble digits amid an ongoing rivalry with United Therapeutics (UTHR). Yutrepia and United's Tyvaso are inhaled treatments for forms of precocious humor unit successful the lungs. During the June quarter, Yutrepia generated $170.4 cardinal successful sales, increasing 31% and beating the Street's…